Seoul Pharma Co., Ltd
Financials
Valuation Metrics
Seoul Pharma Co., Ltd's Market Cap is ₩232B. At end of 2025 it was ₩359B. Ranked #2230 of 2,436 in KR market (top 92%), #1459 of 1,649 on KOSDAQ (top 88%), #224 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 96%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 23.17B KRW | KR#2,230/2,436 Sec#224/234 |
| Revenue | 51.33B KRW | KR#1,756/2,436 Sec#120/234 |
| Net Income | 725.9M KRW | KR#1,447/2,436 Sec#98/234 |
| Total Assets | 70.77B KRW | KR#1,983/2,436 Sec#167/234 |
| Net Assets | 40.86B KRW | KR#2,012/2,436 Sec#177/234 |
| Employees | 176 | KR#1,177/2,436 Sec#97/234 |
| Value | ||
| P/E | 31.92x | KR#1,269/2,436 Sec#79/234 |
| P/B | 0.57x | KR#926/2,436 Sec#43/234 |
| PEG | 2.28x | KR#804/2,436 Sec#54/234 |
| P/S | 0.45x | KR#851/2,436 Sec#30/234 |
| FCF Yield | 4.42% | KR#903/2,436 Sec#49/234 |
| Profitability | ||
| ROE | 1.78% | KR#1,349/2,436 Sec#94/234 |
| ROA | 1.03% | KR#1,316/2,436 Sec#94/234 |
| Op. Margin | -2.63% | KR#1,775/2,436 Sec#123/234 |
| Revenue Growth | -6.38% | KR#1,753/2,436 Sec#162/234 |
| Earnings Growth | 14.01% | KR#804/2,436 Sec#53/234 |
| Financial Health | ||
| Debt Ratio | 173.21% | KR#1,471/2,436 Sec#168/234 |
| Total Debt | 15.00B KRW | KR#1,473/2,436 Sec#127/234 |
| FCF | 1.02B KRW | KR#1,144/2,436 Sec#86/234 |
| Cash | 18.13B KRW | KR#1,301/2,436 Sec#100/234 |
| Current Ratio | 2.38x | KR#790/2,436 Sec#96/234 |
| Dividend | ||
| Div. Growth | 0.00% | KR—/2,436 Sec—/234 |
| Performance | ||
| 1Y Return | -40.33% | KR#1,843/2,436 Sec#163/234 |
| 1M Return | -11.29% | KR#1,841/2,436 Sec#186/234 |
| From 52W High | -41.56% | KR#828/2,436 Sec#58/234 |
| 1Y MDD | -42.54% | KR#613/2,436 Sec#48/234 |
| Trading | ||
| Volume | 9,356 shares | KR#2,135/2,436 Sec#213/234 |
| Foreign Own. | 1.97% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | 62 KRW | KR#1,427/2,436 Sec#100/234 |
| BPS | 3,504 KRW | KR#1,709/2,436 Sec#130/234 |
Company Info
Established in 1985 and listed on KOSDAQ in 2000, this pharmaceutical company produces drugs such as antihypertensive Ator, stroke treatment Plavel, and obesity treatment Weltmin. It leverages SmartFilm® Technology for oral disintegrating film manufacturing, supplying products to partners like Pfizer Korea. The company is preparing new and generic drugs for chronic diseases like hyperlipidemia, gastroesophageal reflux disease, and diabetes to expand market share, with its new Osong plant establishing a foundation for global expansion. Seoul Pharma is headquartered in Cheongju-si, Chungcheongbuk-do.